Bio Expo Online
11.08.2006 Euroscreen Awarded U.S. Patent on Human Nociceptin (ORL1) Receptor:
Euroscreen SA today announced that it has been issued an U.S. patent that covers the use of an important human neurology drug target. The receptor, a G-protein-coupled receptor (GPCR) known as the human nociceptin (ORL1) receptor, is implicated in the control of some key neurological processes, such as pain perception, analgesia, and anxiety. Euroscreen’s patent […]
11.08.2006 CHDI Selects Evotec as Strategic Drug Discovery Partner in the Search for Huntington Disease Treatments:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that CHDI, Inc., a not-for profit organisation pursuing a biotech approach to finding therapies for Huntington Disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programmes.
Since March 2006, Evotec and CHDI have signed four agreements covering medicinal chemistry, assay […]
11.08.2006 BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma:
SAN DIEGO, Aug. 10 /PRNewswire/ — BrainCells Inc. (BCI) today announced it has in-licensed a clinical-stage compound from Mitsubishi Pharma Corp. (MPC) that BCI will reposition and develop for the treatment of central nervous system (CNS) diseases, including mood disorders.
MPC extensively developed the compound for another CNS indication, then suspended the program when the drug […]
25.08.2006 Labcyte Awarded 27th U. S. Patent Describing Acoustic Transfer for the Preparation of Protein Microarrays:
Labcyte Inc. has announced the issuance of U.S. Patent 7,090,333 describing the use of acoustic droplet ejection (ADE) for the preparation of microarrays of proteins and peptides.
ADE uses sound to move fluids eliminating all physical contact with the liquid being transferred.
This disposes of the need for pin tools, pipettes and nozzles that are currently used […]
25.08.2006 Snail Toxin May Spur New Meds Against Brain Disease:
Newswise — University of Utah researchers isolated an unusual nerve toxin in an ocean-dwelling snail, and say its ability to glom onto the brain’s nicotine receptors may be useful for designing new drugs to treat a variety of psychiatric and brain diseases.
“We discovered a new toxin from a venomous cone snail that may enable scientists […]
25.08.2006 MerLion Pharmaceuticals Pte Ltd Announces The Completion Of Merger With Combinature Biopharm AG And Athelas SA; Closure Of US $30 Million Financing Round:
MerLion Pharmaceuticals Pte Ltd (MerLion) of Singapore, the world’s leading natural products based drug discovery company, announces that it has completed a merger by exchange of shares with Combinature Biopharm AG (Berlin, Germany) and Athelas SA (Geneva, Switzerland).
new | february 2007 | january 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004